Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Details : ASN004 incorporates a novel single-chain Fv-Fc antibody linked to a clinically validated Auristatin F hydroxypropylamide cytotoxic payload and drug to antibody ratio of approximately 10-12. In preclinical, a single dose of ASN004 achieved complete and du...
Product Name : ASN004
Product Type : Antibody-drug Conjugate
Upfront Cash : Inapplicable
August 04, 2022
Lead Product(s) : Gusacitinib
Therapeutic Area : Dermatology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Asana BioSciences will present additional positive results from a Phase 2b study evaluating the efficacy and safety of its investigational oral JAK kinase family and SYK tyrosine kinase inhibitor gusacitinib in adult patients with moderate-to-severe chro...
Product Name : ASN002
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 21, 2021
Lead Product(s) : Gusacitinib
Therapeutic Area : Dermatology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : ASN007 is an orally bioavailable, potent and selective inhibitor of ERK1/2 designed to potently inhibit the RAS/RAF/MEK/ERK (MAPK) signaling pathway.
Product Name : ASN007
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 20, 2020
Lead Product(s) : Gusacitinib
Therapeutic Area : Dermatology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Gusacitinib achieved rapid, dose-dependent, clinically meaningful, and statistically significant improvement relative to placebo in both the primary and key secondary endpoints of efficacy as early as 2 weeks and the effects were sustained for the durati...
Product Name : ASN002
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 20, 2020
Lead Product(s) : Gusacitinib
Therapeutic Area : Dermatology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : ASN008
Therapeutic Area : Dermatology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Asana BioSciences Announce ASN008 Achieves Positive Results
Details : The results showed that a single application of ASN008 achieved a clinically meaningful reduction in pruritus of ? 4 points on the NRS in 2-3 hours.
Product Name : ASN008
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 03, 2020
Lead Product(s) : ASN008
Therapeutic Area : Dermatology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Gusacitinib
Therapeutic Area : Dermatology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The topline results show that gusacitinib achieved a dose dependent, clinically meaningful, andstatistically significant improvement relative to placebo in both the primary and key secondary endpoints of efficacy.
Product Name : ASN002
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
February 06, 2020
Lead Product(s) : Gusacitinib
Therapeutic Area : Dermatology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable